These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15448028)

  • 21. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
    Donskov F
    Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma.
    Mencoboni MP; Tredici S; Varaldo M; Queirolo G; Durand F; Rebella L; Galbusera V; Pannacciulli IM; Ghio R
    Neoplasma; 2006; 53(4):333-6. PubMed ID: 16830062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
    Capuron L; Ravaud A; Miller AH; Dantzer R
    Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic renal cancer and patient survival as a criterion of treatment response.
    Stathopoulos GP; Koutantos J; Rigatos SK; Stathopoulos J; Batzios S; Batziou C
    Oncol Rep; 2008 Feb; 19(2):477-81. PubMed ID: 18202797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytokine treatment of renal cell carcinoma].
    Tazaki H
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):29-36. PubMed ID: 8291913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment for renal cancer: are we beyond the cytokine era?
    Ramsey S; Aitchison M
    Nat Clin Pract Urol; 2006 Sep; 3(9):478-84. PubMed ID: 16964189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapy of metastatic kidney cancer].
    Négrier S; Mercatello A; Coronel B; Merrouche Y; Bret M; Blay JY; Thiesse P; Clavel M; Moskovtchenko JF; Philip T
    Prog Urol; 1993 Apr; 3(2):187-94. PubMed ID: 8508201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
    Porta C
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
    McDermott DF
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
    Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
    Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax.
    Wittnebel S; Jalil A; Thiery J; DaRocha S; Viey E; Escudier B; Chouaib S; Caignard A
    Eur Cytokine Netw; 2005 Jun; 16(2):123-7. PubMed ID: 15941683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
    Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
    Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
    Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for renal cell cancer in the era of targeted therapy.
    Coppin C
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.
    Wei YC; Sticca RP; Li J; Holmes LM; Burgin KE; Jakubchak S; Bouton-Verville H; Williamson J; Meyer K; Evans L; Martin J; Stephenson JJ; Trocha S; Smith S; Wagner TE
    Oncol Rep; 2007 Sep; 18(3):665-71. PubMed ID: 17671717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemotherapy of melanoma.
    Keilholz U
    Forum (Genova); 2003; 13(2):158-65; quiz 189. PubMed ID: 14732882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Synergetic responses after administration of interleukin-2 and Interferon-alpha combined with gamma knife radiosurgery in a patient with multiple lung and brain metastases: a case report].
    Takada T; Yamada Y; Uno M; Komeda H; Fujimoto Y
    Hinyokika Kiyo; 2005 Jun; 51(6):381-4. PubMed ID: 16050476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.